Search Results - "Bihlet, A."

Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future by Karsdal, M.A, Michaelis, M, Ladel, C, Siebuhr, A.S, Bihlet, A.R, Andersen, J.R, Guehring, H, Christiansen, C, Bay-Jensen, A.C, Kraus, V.B

“…Summary Osteoarthritis (OA) is the biggest unmet medical need among the many musculoskeletal conditions and the most common form of arthritis. It is a major…”
Get full text

Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials by Karsdal, M.A, Byrjalsen, I, Alexandersen, P, Bihlet, A, Andersen, J.R, Riis, B.J, Bay-Jensen, A.C, Christiansen, C

“…Summary Purpose To evaluate the structure-modifying and symptom efficacy, as well as safety and tolerability of oral salmon calcitonin (sCT) formulated with a…”
Get full text

Reflections from the OARSI 2022 clinical trials symposium: The pain of OA—Deconstruction of pain and patient-reported outcome measures for the benefit of patients and clinical trial design by Karsdal, M.A., Tambiah, J., Felson, D., Ladel, C., Nikolov, N.P., Hodgins, D., Bihlet, A.R., Neogi, T., Baatenburg de Jong, C., Bay-Jensen, A.C., Baron, R., Laslop, A., Mobasheri, A., Kraus, V.B.

“…Osteoarthritis (OA) drug development is hampered by a number of challenges. One of the main challenges is the apparent discordance between pain and structure,…”
Get full text

Does moderate intensity impact exercise and non-impact exercise induce acute changes in collagen biochemical markers related to osteoarthritis? – An exploratory randomized cross-over trial by Bjerre-Bastos, J.J., Nielsen, H.B., Andersen, J.R., Karsdal, M., Bay-Jensen, A.-C., Boesen, M., Mackey, A.L., Byrjalsen, I., Bihlet, A.R.

“…To investigate acute changes in biochemical markers of cartilage turnover in response to moderate intensity exercise with and without joint impact in humans…”
Get full text

Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD by Vijverberg, E. G. B., Axelsen, T. M., Bihlet, A. R., Henriksen, K., Weber, F., Fuchs, K., Harrison, J. E., Kühn-Wache, K., Alexandersen, P., Prins, N. D., Scheltens, Philip

“…Abstract Background Varoglutamstat (formerly PQ912) is a small molecule that inhibits the activity of the glutaminyl cyclase to reduce the level of…”
Get full text

OA phenotypes, rather than disease stage, drive structural progression – identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA by Karsdal, M.A, Bihlet, A, Byrjalsen, I, Alexandersen, P, Ladel, C, Michaels, M, Andersen, J.R, Riis, B.J, Kraus, V, Bay-Jensen, A.C, Christiansen, C

“…Summary Background/Purpose The aim of this study was to identify key characteristics of disease progression through investigation of the association of…”
Get full text

Cohort Profile: The Prospective Epidemiological Risk Factor (PERF) study by Neergaard, J S, Dragsbæk, K, Kehlet, S N, Hansen, H B, Hansen, G, Byrjalsen, I, Alexandersen, P, Lindgren, L M, Bihlet, A R, Riis, B J, Andersen, J R, Qvist, P, Karsdal, M A, Christiansen, C

Get full text

A Genetic Validation of the Neurodegeneration Biomarkers Tau-A and Tau-C - A Mendelian Randomization Study by Axelsen, T. M., Bager, C., Bihlet, A., Karsdal, M. A., Henriksen, K., Tang, M. H. E.

“…Background Disease modifying treatments for dementia are only just surfacing, and their development is still significantly hindered by the lack of validated…”
Get full text

Serum Tau-A and Tau-C Levels and Their Association with Cognitive Impairment and Dementia Progression in a Memory Clinic Derived Cohort by Axelsen, Tobias Melton, Høgh, P., Bihlet, A. R., Karsdal, M. A., Henriksen, K., Hasselbalch, S. G., Simonsen, A. H.

“…Background Serum-measured fragments of Tau cleaved by ADAM-10 (Tau-A) and Caspase-3 (Tau-C) have been found linked to change in cognitive function and risk of…”
Get full text

Investigating clinical differences of three different osteoarthritis phenotypes identified by two clinically tested biomarkers by Bay-Jensen, A.-C, Bihlet, A, Andersen, J.R, Byrjalsen, I, Riis, B.J, Christiansen, C, Karsdal, M.A

Get full text

Elevated levels of CRPM, an inflammatory biomarker correlating with disease activity in RA, are prognostic of radiographic knee OA by Bay-Jensen, A.-C, Bihlet, A, Byrjalsen, I, Andersen, J, He, Y, Siebuhr, A, Thudium, C, Guehring, H, Michaelis, M, Ladel, C, Juel Riis, B, Christiansen, C, Karsdal, M.A

Get full text

Elevated levels of CRPM, an inflammatory biomarker correlating with disease activity in RA, are prognostic of radiographic knee OA by Bay-Jensen, A.-C, Bihlet, A, Byrjalsen, I, Andersen, J, He, Y, Siebuhr, A, Thudium, C, Guehring, H, Michaelis, M, Ladel, C, Juel Riis, B, Christiansen, C, Karsdal, M.A

Get full text

Identification of an inflammatory phenotype with higher likelihood of progression in OA: Analysis of womac pain sub-questions, C3M and U-CTX-II from two phase 3 randomized clinical trials with treatment of symptomatic knee osteoarthritis by Bay-Jensen, A.C, Byrjalsen, I, Musa, K, Bihlet, A, Alexandersen, P, Andersen, J.R, Riis, B.J, Christiansen, C, Karsdal, M.A

Get full text

Segregating OA patients with and without joint inflammation using two biomarkers of connective tissue inflammation by Bay-Jensen, A.-C, Byrjalsen, I, Bihlet, A, Musa, K, Riis, B.J, Christiansen, C, Karsdal, M.A

Get full text

MRI analysis from two phase 3 randomized clinical trials; treatment of symptomatic knee osteoarthritis with oral salmon calcitonin by Karsdal, M.A, Dam, E.B, Byrjalsen, I, Bihlet, A, Andersen, J.R, Riis, B.J, Alexandersen, P, Bay-Jensen, A.-C, Christiansen, C

Get full text

Deconstructing biomarker analysis in OA: activity, burden of disease and progression by Bay-Jensen, A.-C., Bihlet, A., Thudium, C., Andersen, J.R., Karsdal, M.A.

Get full text

Study design of a phase I, placebo-controlled, First-in-human trial to assess safety and tolerability, immunogenicity, and pharmacokinetics and pharmacodynamics of single ascending doses of the anti-ADAMTS-5 Nanobody®, M6495, in healthy male subjects by Balchen, T., Strotmann, R., Reinstrup Bihlet, A., Sonne, J., Ladel, C., Moreau, F., Guehring, H.

Get full text

Identification of superior responders to a bone and cartilage centric treatment in osteoarthritis: low levels of cartilage formation may provide an opportunity to stimulate formation by Luo, Y., Higgins, N., He, Y., Byrjalsen, I., Andersen, J.R., Bihlet, A., Karsdal, M., Bay-Jensen, A.

Get full text

Assessment of cartilage markers in synovial fluid from the forward study provide insight to the biphasic effect of sprifermin by Bay-Jensen, A.-C., Manginelli, A., Moreau, F., He, Y., Luo, Y., Bihlet, A., Andersen, J.R., Karsdal, M.A., Guehring, H., Ladel, C.

Get full text

Efficacy and safety of intra-articular Sprifermin in symptomatic radiographic knee osteoarthritis: pre-specified analysis of 3-year data from a 5-year randomized, placebo-controlled, phase II study by Hochberg, M., Guermazi, A., Guehring, H., Aydemir, A., Wax, S., Fleuranceau-Morel, P., Reinstrup Bihlet, A., Byrjalsen, I., Ragnar Andersen, J., Eckstein, F.

Get full text